Aspire Biopharma Launches $5 Million Share Repurchase Program
Aspire Biopharma issued the following letter to shareholders from Chief Executive Officer Kraig Higginson. "2026 is shaping up to be a defining year for Aspire Biopharma Holdings. We are moving with speed to transform our clinical pipeline into commercial reality, broadening the market reach of our high growth consumer segment, while simultaneously diversifying our business through a proposed strategic acquisition... Our Board of Directors recently authorized a $5.0 million share repurchase program, a move that underscores our absolute confidence in Aspire's intrinsic value... We are making progress on our clinical pipeline, driving the commercial ramp of our BUZZ BOMB(TM) product, and are better capitalized. With an opportunity to become more strategically diverse through the acquisition of DCS, we believe these initiatives set the stage for meaningful growth... Whether through the laboratory, the retail shelf, or the disciplined repurchase of our own shares, our priority remains the same: driving long-term value. In closing, I would emphasize the question all should be asking, "How is it with all of the above items in process, and many completed, and with more than $12 million cash in the bank after closing our recent financing in April, along with the proposed acquisition of a $200 million + Revenue Company, with over $20 million in EBITDA, how can the public markets only value us at approximately $7 million today?" To our shareholders, thank you for your trust and partnership. We remain focused on delivering economic return through innovation, execution, and strategic growth."
